Skip to main
ACIU

AC Immune (ACIU) Stock Forecast & Price Target

AC Immune (ACIU) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AC Immune is a clinical-stage biotechnology company with a broad pipeline of therapeutic and diagnostic products targeting neurodegenerative diseases, including Alzheimer's and Parkinson's. Their expertise in precision medicine and use of proprietary technology platforms sets them apart from competitors. With a strong pipeline and potential for partnering agreements, AC Immune has significant potential for long-term growth.

Bears say

AC Immune is an established drug development company, and as with any company in this industry, it faces many risks such as unexpected outcomes in clinical trials, regulatory uncertainty, and complex and price-sensitive commercial markets. Additionally, the company had a net loss of CHF 14.8M for the quarter and expects current cash resources to cover operations for the next 12 months. This, combined with decreased R&D expenses, may indicate a lack of progress or potential setbacks in their pipeline.

AC Immune (ACIU) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AC Immune (ACIU) Forecast

Analysts have given AC Immune (ACIU) a Strong Buy based on their latest research and market trends.

According to 1 analysts, AC Immune (ACIU) has a Strong Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AC Immune (ACIU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.